Search results
- Specifically, recurrent somatic PIK3CA variants identified in canine mammary tumors and hemangiosarcomas are comparable to human hotspot mutations such as H1047R. PIK3CA mutations found in canine tumors encode functional proteins that may alter downstream PI3K/Akt/mTOR signaling pathway.
pubmed.ncbi.nlm.nih.gov/32932196/
People also ask
What are PIK3CA gain-of-function mutations?
What are PIK3 mutations?
What are PIK3CA -related disorders?
Can PIK3CA mutations be found in combined lymphatic-venous malformations (LVM)?
Does PIK3CA cause generalized lymphatic anomaly?
What vascular anomalies are associated with PIK3CA variants?
Mutations in PIK3CA gene are frequently observed in human solid cancers, and also appear to occur in canine tumors. Specifically, recurrent somatic PIK3CA variants identified in canine mammary tumors and hemangiosarcomas are comparable to human hotspot mutations such as H1047R.
- Molecular Profile of Canine Hemangiosarcoma and Potential ...
Typical mutations in dogs with HSA occur in the TP53 genes,...
- Dysregulation of PI3K/Akt/PTEN Pathway in Canine Mammary Tumor
The PI3K/Akt/PTEN axis is one of the most important...
- Molecular Profile of Canine Hemangiosarcoma and Potential ...
Typical mutations in dogs with HSA occur in the TP53 genes, commonly called the “guardian of the genome”, and PIK3CA, active in the PI3K-AKT-mTOR cell proliferation signaling pathway [41,43,44].
- Sirolimus
- Miransertib
- Alpelisib
Sirolimus inhibits mTOR, which is a node in the PI3K signaling pathway, and has been investigated in several clinical trials in patients with vascular malformations and overgrowth disorders [1, 6, 21, 53, 54]. Sirolimus is currently used in an off-label capacity to treat these disorders [36, 57]. Sirolimus has shown efficacy in multiple phase 2 stu...
Miransertib, an oral, allosteric inhibitor of AKT, demonstrated antiproliferative activity in primary fibroblasts derived from patients (N = 6) with PIK3CA-related disorders in the presence or absence of growth factors . In preliminary results of an open-label, phase 1/2 study of miransertib in patients (N = 15) with PIK3CA-related Overgrowth Spect...
Alpelisib selectively inhibits PI3Kα and therefore directly targets the effects of PIK3CA activating mutations [55, 77]. In a study in human umbilical vein endothelial cells with PIK3CA or TEK mutations, alpelisib reversed abnormal AKT phosphorylation, cell morphology, and extracellular fibronectin levels—further highlighting the connection between...
- Guillaume Canaud, Adrienne M. Hammill, Denise Adams, Miikka Vikkula, Kim M. Keppler-Noreuil
- 2021
Oct 31, 2023 · This review aims to delineate the pertinent aspects of the PI3K-AKT-mTOR signaling pathway in health and in tumor development. It will then present a synopsis of current understanding of PI3K-AKT-mTOR signaling in important canine cancers and advancements in targeted inhibitors of this pathway.
Jul 12, 2021 · The PI3K/Akt/PTEN axis is one of the most important signaling pathways in tumorigenesis. Recently, mutation of PIK3CA has been highlighted due to the similarities of mutational hotspots in both dogs and humans.
- Soo-Hyeon Kim, Byung-Joon Seung, Seung-Hee Cho, Ha-Young Lim, Min-Kyung Bae, Jung-Hyang Sur
- 10.3390/ani11072079
- 2021
- Animals (Basel). 2021 Jul; 11(7): 2079.
Dec 1, 2020 · PIK3CA mutations found in canine tumors encode functional proteins that may alter downstream PI3K/Akt/mTOR signaling pathway. Therefore, PI3K inhibitors have potential in cancer therapy for dogs.
Dec 1, 2020 · Mutations in PIK3CA gene are frequently observed in human solid cancers, and also appear to occur in canine tumors. Specifically, recurrent somatic PIK3CA variants identified in canine mammary tumors and hemangiosarcomas are comparable to human hotspot mutations such as H1047R.
